Qiagen NV (CHIX:QIAD) Total Long-Term Assets: €3,669 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:QIAD Qiagen NV CHIX:QIAD
68 GF Score
Price €35.56
GF Value €45.27
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Qiagen NV Total Long-Term Assets?

Qiagen NV CHIX:QIAD 68 Total Long-Term Assets is €3,669 Mil as of Mar. 2026. GuruFocus rates CHIX:QIAD with a GF Score™ of 68/100 and a GF Value™ of €45.27 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Qiagen NV's Total Long-Term Assets for the quarter that ended in Mar. 2026 was €3,669 Mil.

Qiagen NV Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Qiagen NV's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV Total Long-Term Assets Chart

Qiagen NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,573.06 3,675.73 3,638.32 3,561.93 3,660.38

Qiagen NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,517.31 3,472.14 3,427.22 3,660.38 3,669.17
CHIX:QIAD
68GF Score
Qiagen NV CHIX:QIAD
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qiagen NV Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €3,669 Mil mean?
Qiagen NV (CHIX:QIAD) has a Total Long-Term Assets of €3,669 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Qiagen NV and its competitors.
Is Qiagen NV's Total Long-Term Assets too high?
Qiagen NV's current Total Long-Term Assets is €3,669 Mil. Overall, Qiagen NV has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Total Long-Term Assets compare to CRL and BLLN?
Qiagen NV's Total Long-Term Assets of €3,669 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Diagnostics & Research company?
A good Total Long-Term Assets depends on the Medical Diagnostics & Research industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Qiagen NV and its competitors. Qiagen NV's current Total Long-Term Assets is €3,669 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (CHIX:QIAD) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.27, compared to a current price of €35.56 — trading 21.5% below its estimated fair value. The current Total Long-Term Assets is €3,669 Mil. Qiagen NV's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Qiagen NV (CHIX:QIAD), the current Total Long-Term Assets is €3,669 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qiagen NV (CHIX:QIAD) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €35.56 is trading 21.5% below its estimated GF Value™ of €45.27. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for CHIX:QIAD:

  • Total Long-Term Assets: €3,669 Mil
  • GF Value™: €45.27 vs. price of €35.56 (21.5% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the CHIX:QIAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
68GF Score

Get the complete analysis for CHIX:QIAD

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.56
Price
€45.27
GF Value